BRÈVE

sur VALBIOTIS (EPA:ALVAL)

Valbiotis Expands Product Range with Menopause Solution

Graphique de l'évolution du cours de l'action VALBIOTIS (EPA:ALVAL).

Valbiotis SA, a French laboratory, has launched ValbiotisPLUS® Menopause & Perimenopause, a new addition to their dietary supplement line. This product, available from February 3, aims to support women's health during menopause and perimenopause. The ValbiotisPLUS® range focuses on cardio-metabolic balance, expanding to eleven products, including the new menopause supplement.

The latest addition comes amid growing demand for menopause-related health products, with French pharmacy sales hitting €21.4 million in 2024. Valbiotis leverages scientific literature for a hormone-free solution, emphasizing a comprehensive metabolic health approach.

Valbiotis plans a marketing push targeting both pharmacy and e-commerce channels to maximize reach. Shareholders benefit from a 20% discount on the product range. The launch highlights Valbiotis' commitment to addressing significant health issues with natural ingredients and scientific backing.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de VALBIOTIS